uniQure to Announce First Quarter 2025 Financial Results

Core Insights - uniQure N.V. will report its first quarter 2025 financial results on May 9, 2025, before market open, and will host an earnings call at 8:30 a.m. ET to provide updates on its pipeline and AMT-130 [1] - The company is initiating quarterly earnings calls to enhance engagement with the investment community as it progresses towards a BLA submission and potential commercialization [1] Company Overview - uniQure is a leading gene therapy company focused on delivering transformative therapies for patients with severe medical needs, including a gene therapy for hemophilia B, which marks a significant milestone in genomic medicine [3] - The company is advancing a pipeline of proprietary gene therapies targeting Huntington's disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and other severe diseases [3]